Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia

References

• Barnes TRE, Joyce EM. Antipsychotic drug treatment: recent advances. C1117: Opin. Psychiatry 14(1), 25–37 (2001).
   Google Scholar
• •Comprehensive review of novel antipsychotic drug therapy.
   Google Scholar
• Nasrallah HA, Mulvihill T. Iatrogenic disorders associated with conventional is. atypical antipsychotics.Ann. Clin. Psychiatry 13(4), 215–27 (2001).
   Google Scholar
• Barnes TRE, McPhillips MA. Critical analysis and comparison of the side effect and safety profiles of the new antipsychotics. Br. Psychiatry174(38S), 34–43 (1999).
   Google Scholar
• Fleischhacker WW The psychopharmacology of schizophrenia. Cur Opin. Bychiatry 12,53–59 (1999).
   Google Scholar
• Arana GW. An overview of side effects caused by typical antipsychotics. j Clin. Bychiatry61\(Suppl. 8), 5–13 (2000).
   Google Scholar
• •Comprehensive review of the side effects of antipsychotic drug therapy.
   Google Scholar
• Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am. j Health Syst. Phatm 57(3), 238–55 (2000).
   Google Scholar
• ••Comprehensive review of novelantipsychotic drug therapy.
   Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BE Merl 321(7273), 1371–1376 (2000).
   Google Scholar
• ••Impressive and comprehensive meta-analysis of data comparing typical and atypical antipsychotic agents. The authors conclude that there is no clear evidence that atypical antipsychotics are more effective or are better tolerated than typical antipsychotics.
   Google Scholar
• Rice DR The economic impact of schizophrenia. j Clin. Ptychiatry60, 4–6 (1999).
   Google Scholar
• Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents. Aimj Psychiatry159,103–108 (2002).
   PubMed Web of Science ®Google Scholar
• Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J. Clin. Psychiatry58\(Suppl. 10), 50–54 (1997).
   Google Scholar
• Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EE Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Ptychophatmacol Bull. 34, 373–382 (1998).
   PubMedGoogle Scholar
• Finley PR, Sommer BR, Corbitt JL, Brunson GH, Lum BL. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Ptychopharmacol Bull. 34,75–81 (1998).
   PubMedGoogle Scholar
• Brown, CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: Part II: Adverse effects, drug interactions and costs. Ann. Pharmacother 33(2), 210–217 (1999).
   Google Scholar
• Galvin PM, Knezek LD, Rush AJ, Toprac MG, Johnson B. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clin. Ther 21,1105–1116 (1999).
   Google Scholar
• Oh PI, Iskedjian M, Addis A, Lanctot K, Einarson TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can. J. Clin. Pharmacol 8(4), 199–206 (2001).
   Google Scholar
• Meltzer HY, Burnett S, Bastani B, Ramirez LE Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hasp. Community Ptychiatry41,892–897 (1990).
   PubMedGoogle Scholar
• Revicki DA, Ehreth JL. Health-related quality-of-life assessment and planning for the pharmaceutical industry. Clin. Ther 19(5), 1101–1115 (1997).
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN, Heslegrave RJ, Hogan TE Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int. Clin. Ptychophatmacol 11 (Suppl. 2), 55–59 (1996).
   Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 23,637–651 (1997).
   PubMed Web of Science ®Google Scholar
• Lader, M. Some adverse effects of antipsychotics: prevention and treatment. J. Clin. Rychiatry60\(Suppl. 12), 18–21 (1999).
   Google Scholar
• Cabeza IG, Amador MS, Lopez CA, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res. 41,349–355 (2000).
   PubMed Web of Science ®Google Scholar
• Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol 10\(Suppl. 3), 133–138 (1995).
   Google Scholar
• ••Describes a self-rating scale developed tomeasure SWN.
   Google Scholar
• Wallace M. Real progress — the patient's perspective. Int. Clin. Rychopharmacol 16\(Suppl. 1), S21—S24 (2001).
   Google Scholar
• Ritsner M, Ponizovsky A, Endicott J et al Relatively small impact adverse events of antipsychotics on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychophatmacol 12,31–38 (2002).
   PubMed Web of Science ®Google Scholar
• Day J, Bentall R, Wood G, Dewey M. A self-rating scale for measuring neuroleptic side effects: validation in a group of schizophrenic patients. BE j Psychiatry 166(5), 650–653 (1995).
   PubMedGoogle Scholar
• •Describes a self-rating scale developed to measure side effects of antipsychotic treatment.
   Google Scholar
• Morrison P, Gaskill D, Meehan T, Lunney P, Lawrence G, Collings P The use of the Liverpool University Neuroleptic Side effect Rating Scale (LUNSERS) in clinical practice. Aust. NZJ Ment. Health NUIN. 9, 166–176 (2002).
   Google Scholar
• •Describes a rating scale developed to measure side effects of neuroleptic treatment.
   Google Scholar
• Ritsner M, Modai I, Rivkin 0, Bystrov E, Nehamkin Y, Ponizovsky A. Distress scale for adverse symptoms: a new instrument for measuring the relationship between adverse drug symptoms and associated distress. Eur. Neuropsychopharmacol 9, 258 (1999).
   Google Scholar
• •Describes an instrument including a rating scale for the assessment of side effects and self-reported psychological DSAS.
   Google Scholar
• Ritsner M, Modai I, Endicott J et al Differences in Quality of Life Domains, Psychopathological and Psychosocial Factors in Psychiatric Patients. j Clin. Ptychiatry61, 880–889 (2000).
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat) . Notyl j Ptychiatry55 (Suppl. 44), 5–69 (2001).
   Google Scholar
• •Describes a self-rating scale developed to measure side effects of neuroleptic treatment.
   Google Scholar
• Djikers M. Measuring quality of life: methodological issues. Am. J. Phys. Merl Rehabil 78(3), 286–300 (1999).
   Google Scholar
• Wilson TB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JA/V/A 273,59–65 (1995).
   Google Scholar
• WHOQOL Group. The World Health Organization Quality of Life Assessment (VVH0Q0L): Position paper from the World Health Organization. Soc. Sri. Med. 41,1403-1409 (1995).
   Google Scholar
• Lehman A. Measures of quality of life among persons with severe and persistent mental disorders. Soc. Psychiatry Psychiatr Epidemiol 31,78–88 (1996).
   PubMed Web of Science ®Google Scholar
• Priebe SI, Roeder-Wanner UU, Kaiser W Quality of life in first-admitted schizophrenia patients: a follow-up study. Ptychol Merl 30,225–230 (2000).
   PubMedGoogle Scholar
• Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hasp. Community Psychiatry 43, 262–265 (1992).
   PubMedGoogle Scholar
• Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 6(1), 21–26 (1997).
   PubMed Web of Science ®Google Scholar
• ••Assesses the impact of side effects on Q01,of schizophrenia patients in a regression model.
   Google Scholar
• Van Nieuwenhuizen C, Schene AH, Boevink WA, Wolf JRLM. Measuring the quality of life of clients with severe mental illness: a review of instruments. Bychiatr Rehabil 20,33–41 (1997).
   Web of Science ®Google Scholar
• Awad AG, Voruganti LN, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. PhatmacoEconomics 11(1), 32–47 (1997).
   Google Scholar
• Bishop SL, Walling DP, Dott SG, Folkes CC, Bucy J. Refining quality of life: validating a multidimensional factor measure in the severe mentally ill. Qual Life Res. 8,151–160 (1999).
   PubMed Web of Science ®Google Scholar
• Bullinger M, Naber D. Assessing the quality of life in mental illness. In: Contemporary psychiatry Vol. I. Henn FA, Sartorius N, Helmchen H, Lauter H (Eds). Springer, Berlin, Germany, 135–150 (2001).
   Google Scholar
• •• Comprehensive methodological review about measuring QoL not only in schizophrenia, but also in other areas of psychiatry
   Google Scholar
• Hawthorne G, Richardson J. Measuring the value of program outcomes: a review of multiattribute utility measures. Expert Rev Pharmacoeconomics Outcomes Res. 1 (2), 215–228 (2001).
   Google Scholar
• ••Well-written review evaluating QoLinstruments.
   Google Scholar
• Fitzgerald PB, Williams CL, Corteling N et al Subject and observer-rated quality of life in schizophrenia. Acta. PTchiati: Scand.103, 387–392 (2001).
   PubMed Web of Science ®Google Scholar
• ••The relationship between objectively-ratedQoL and subjective measures of social functioning and life satisfaction was examined in 193 schizophrenia patients.
   Google Scholar
• Ruggeri M, Bisoffi G, Fontecedro L, Warner R. Subjective and objective dimensions of quality of life in psychiatric patients: a factor analytical approach: The South Verona Outcome Project 4. BE j Psychiatry 178,268–275 (2001).
   PubMed Web of Science ®Google Scholar
• Heinrichs DW, Hanlon TE, Carpenter WT The Quality of Life Scale: an instrument for rating the schizophrenic deficit scale. Schizophr Bull. 10,388–398 (1984).
   PubMed Web of Science ®Google Scholar
• Cramer J, Rosenheck R, Xu W Henderson W, Thomas J, Chamey D. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull 27(2), 227–234 (2001).
   Google Scholar
• •In-depth discussion of the relationship between observer-assessed QoL and psychopathology of schizophrenia.
   Google Scholar
• Katschnig H. How useful is the concept of quality of life in psychiatry? Curl: Opin. Psychiatry 10,337–345 (1997).
   Google Scholar
• Kaiser W Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life. BE j Psychiatry 176,92–93 (2000).
   Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. fiychopharmacol Bull 29,321–326 (1993).
   PubMed Web of Science ®Google Scholar
• •Discusses a comprehensive perceived QoL inventory
   Google Scholar
• Ritsner M, Kurs R, Kostizky H, Ponizovsky A, Modai I. Subjective quality of life in severely mentally ill patients: a comparison of two instruments Qual Life Res. [In Press] (2002).
   Google Scholar
• Lehman AF, Ward NC, Linn LS. Chronic mental patients: The quality of life issue. Am.PTchiatry 139,1271–1276 (1982).
   Google Scholar
• ••Landmark paper describing health-relatedQoL, which initiated the study of this topic.
   Google Scholar
• Lehman AF Measuring quality of life in a reformed health system. Health Affairs 14(3), 90–101 (1995).
   Google Scholar
• Oliver J, Huxley P, Bridges K. Mohammed H. Quality of Life and Mental Health Service. Routledge, London, UK (1996).
   Google Scholar
• Lehman AF The well-being of chronic mental patients: Assessing their quality of life. Arch. Gen. PTchiatry 40, 369–373 (1983).
   Google Scholar
• Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am. j Psychiatry 154,99–105 (1997).
   Google Scholar
• Voruganti L, Heslegrave R, Awad AG, Seeman MV. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. fiychol Med. 28,165–172 (1998).
   PubMed Web of Science ®Google Scholar
• Lehman AF, Postrado LT, Rachuba LT Convergent validation of quality of life assessments for persons with severe mental illnesses. Qual Life Res. 2,327–333 (1993).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R, Xu W Thomas J, Henderson W, Charney DS. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Co-operative Study Group on Clozapine in Refractory Schizophrenia. Schizophr Bull. 26(3), 659–666 (2000).
   Google Scholar
• Lenert LA, Ziegler J, Lee T etal Differences in health values among patients, family members and providers of outcome in schizophrenia. Merl Catel0, 1011–1021 (2000).
   Google Scholar
• ••Very informative paper about an issueoften neglected: the different views of patients, their relatives and 'professional helpers'.
   Google Scholar
• Karow A, Naber D. Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration. CI.117: Opin. fiychiatry15(1), 31–36 (2002).
   Google Scholar
• •Informative review including recent clinical trials with emphasis on QoL.
   Google Scholar
• Green CA, Fenn DS, Moussaoui D, Kadri N, Hoffman WF. Quality of life in treated and never-treated schizophrenic patients. Acta fisychiati: Scand 103(2), 131–142 (2001).
   Web of Science ®Google Scholar
• Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. fiychopharmacol Bull. 32, 683–697 (1996).
   PubMedGoogle Scholar
• Rosenheck R, Tekell J, Peters J etal Does participation in psychosocial treatment augment the benefit of clozapine? Arch. Gen. fiychiatry55, 618–625 (1998).
   Google Scholar
• Bobes J, Gutierrez M, Gibert J, Gonzales MP. Quality of Life in Schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic out-patients undergoing risperidone maintenance treatment. Eur. Psychiatry 13,158–163 (1998).
   Google Scholar
• Franz M, Lis S, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Brj Rychiatry170, 422–425 (1997).
   Google Scholar
• Hamilton SH, Revicki DA, Edgell ET eta]. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. PharmacoEconomics 15,469–480 (1999).
   Google Scholar
• Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. (Alai Life Res. 5,417–426 (1999).
   Google Scholar
• Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int. Clin. Psychopharmacol 15,245–255 (2000).
   PubMed Web of Science ®Google Scholar
• •Atypical antipsychotic agents are not only more effective on negative, cognitive and affective symptoms, but (at least olanzapine in this trial) improve the chances of employment.
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ etal Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. PTchopharmacol 17, 407–418 (1997).
   PubMed Web of Science ®Google Scholar
• Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J. Clin. Psychiatry 60, 658–663 (1999).
   PubMed Web of Science ®Google Scholar
• Colonna L, Saleem P, Dondey-Nouvel L, Rein W Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int. Gun. P9rhophatmacol 15,13–22 (2000).
   Google Scholar
• Saleem P, Olie JP, Loo H. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int. Clin. Psychopharmacol 17, 1–8 (2002).
   Google Scholar
• Awad AG, Lapierre YD, Angus C, Rylander A. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. I Psychiatry Neurosci. 22(4), 244–248 (1997).
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L et al Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr. Res. 43,135–145 (2000).
   PubMed Web of Science ®Google Scholar
• ••In a study of major clinical relevance, 230 patients were treated with either atypical or typical antipsychotic agents. Interestingly, the authors concluded that self- and clinician-rated Q0L outcomes of antipsychotic therapy were contradictory.
   Google Scholar
• Tempier R, Pawliuk N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J. Psychiatry Neurosci. 26,131–136 (2001).
   Web of Science ®Google Scholar
• •The authors found that the type of antipsychotic medication taken did not influence satisfaction with life scores.
   Google Scholar
• Browne S, Garavan J, Gervin M, Roe M, Larkin C, O'Callaghan E. Quality of life in schizophrenia: insight and subjective response to neuroleptics. I Net-v. Ment. Dis. 186(2), 74–78 (1998).
   Google Scholar
• Gerlach J, Larsen EB. Subjective experience and mental side effects of antipsychotic treatment. Acta PFhiatr Scand. 98\(Suppl. 395), 113–117 (1999).
   Google Scholar
• Kemmler G, Meise U, Tasser A eta]. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta PFhiatr Scam/. 89,118–124 (1994).
   Google Scholar
• Demovsek MZ, Prevolinik Rupel V, Rebolj M, Tavcar R. Quality of life and treatment costs in schizophrenic out-patients, treated with depot neuroleptics. Eur. Psychiatiy16, 474–482 (2001).
   PubMed Web of Science ®Google Scholar